DS-1205b free base

DS-1205b free base is a potent and selective inhibitor of AXL kinase , with an IC 50 of 1.3 nM. DS-1205b free base also inhibits MER , MET , and TRKA , with IC 50 s of 63, 104, and 407 nM, respectively. DS-1205b free base can inhibit cell migration in vitro and tumor growth in vivo In Vitro DS-1205b (0.3-33 μM; 2-24 h) inhibits hGAS6-induced migration in NIH3T3-AXL cells (EC 50 =2.7 nM). DS-1205b (1-10000 μM; 2-24 h) significantly inhibits the phosphorylation of AXL in NIH3T3-AXL cells. DS-1205b decreases NIH3T3 cell proliferation but not obviously inhibits growth (GI 50 >10,000 nM). MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: NIH3T3-AXL cells Concentration: 1, 10, 100, 1000, 10000 μM Incubation Time: 2, 24 hours Result: Completely inhibited the phosphorylation of AXL at concentrations above 10 nM. Slightly inhibited the phosphorylation of AKT serine/threonine kinase in a dose-dependent manner. In Vivo DS-1205b (3.1-50 mg/kg; p.o. bid for 5 d) exhibits pAXL inhibition mediated antitumor effects in mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female NOD/Shi-scid IL-2Rγ KO Jic mice were implanted with NIH3T3-AXL tumor blocks Dosage: 3.1, 6.3, 13, 25, 50 mg/kg Administration: P.o. twice daily for 5 days Result: Inhibited tumor growth by 39-94%. Reduced the phosphorylation of both AXL and AKT in tumors. Form:Solid IC50& Target:AXL 1.3 nM (IC 50 ) MER 63 nM (IC 50 ) TrkA 407 nM (IC 50 ) Met 104 nM (IC 50 )

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet